Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2007-08-14
2007-08-14
Devi, S. (Department: 1645)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C530S300000, C530S806000, C530S825000, C424S244100, C424S234100, C424S190100, C424S237100, C424S185100, C514S002600
Reexamination Certificate
active
10412026
ABSTRACT:
Novel vaccines for use against β-hemolyticStreptococcuscolonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of streptococcal C5apeptidase (SCP). Also disclosed is a method of protecting a susceptible mammal against β-hemolyticStreptococcuscolonization or infection by administering such a vaccine. Enzymatically inactive SCP, and polynucleotides encoding these SCP proteins are further disclosed.
REFERENCES:
patent: 4454121 (1984-06-01), Beachey
patent: 4695562 (1987-09-01), Beachey et al.
patent: 4772584 (1988-09-01), Cleary et al.
patent: 5124153 (1992-06-01), Beachey et al.
patent: 5162226 (1992-11-01), Beachey et al.
patent: 5846547 (1998-12-01), Cleary
patent: 6100380 (2000-08-01), Green et al.
patent: 6270775 (2001-08-01), Cleary
patent: 6355255 (2002-03-01), Cleary et al.
patent: 6951653 (2005-10-01), Cleary et al.
patent: 2004/0052801 (2004-03-01), Cleary et al.
patent: 2005/0136068 (2005-06-01), Cleary et al.
patent: 2006/0153879 (2006-07-01), Cleary et al.
patent: WO 89/09063 (1989-10-01), None
patent: WO-89/09064 (1989-10-01), None
patent: WO-93/14198 (1993-07-01), None
patent: WO-93/21220 (1993-10-01), None
patent: WO-94/06421 (1994-03-01), None
patent: WO-94/06465 (1994-03-01), None
patent: WO-95/28960 (1995-11-01), None
patent: WO-97/26008 (1996-01-01), None
The Concise Encyclopedia: Biochemistry and Molecular Biology, (Ed) Scott et al. Third Edition, Walter de Gruyter, New York, p. 489, (1997).
Alexander et al., “Amino acid changes affecting the activity of pneumolysin alter the behaviour of pneumococci in pneumonia”,Mircob Pathog., 24(3), 167-174 (1998).
Anderson et al., “Processing, stability, and kinetic parameters of C5a peptidase fromStreptococcus pyogenes,” Eur. J. Biochem., 269, 4839-4851 (2002).
Cheng et al., “The Group BStreptococcalC5a Peptidase Is Both a Specific Protease and an Invasin,”Infection and Immunity, 70, 2408-2413 (2002).
Feldman et al., “Pneumolysin induces the salient histologic features of pneumococcal infection in the rat lung in vivo”,Am J Respir Cell Mol Biol.,5(5), 416-423 (1991).
Houghten et al. Vaccines86, Cold Spring Harbor Laboratory, p. 21-25, (1986).
Lazar et al., “Transforming growth factor alpha: Mutation of aspartic acid 47 and leucine 48 results in different biological activities”,Moll Cell Biol., 8(3), 1247-1252 (1988).
Mitchell et al., “Complement activation and antibody binding by pneumolysin via a region of the toxin homologous to a human acute-phase protein”,Mol Microbiol., 5(8), 1883-1888 (1991).
Berg, Andreas , et al., “StreptococcalCysteine Proteinase Releases Biologically Active Fragments ofStreptococcalSurface Proteins”,The Journal Of Biological Chemistry, 270(17), (1995),9862-9867.
Bessen, D. , et al., “Influence of Intranasal Immunization with Synthetic Peptides Corresponding to Conserved Epitodes of M Protein on Mucosal Colonization by Group AStreptococci”, Infection and Immunity, 56(10), (1988),2666-2672.
Bessen, D , et al., “Synthetic Peptide Vaccine Against Mucusal Colonization by Group AStreptococci. I. Protection Against a Heterologous M Serotype with Shared C Repeat Region Epitopes”,J Immunol, 145(4), (1990), 1251-1256.
Booth, S. , et al., “Dapsone Suppresses Integrin-Mediated Neutrophil Adherence Function”,The Journal of Investigative Dermatology, 98(2), (1992),135-140.
Boyle, M. , et al., “Measurement of Leukocyte Chemotaxis in Vivo”,Methods in Enzymology, 162, (1988),101-114.
Bronze, M. , et al., “Epitopes of group AstreptococcalM protein that envoke cross-protective local immune responses”,J. Immunol., 148(3), (1992),888-893.
Bronze, M. , et al., “Protective Immunity Evoked by Locally Administered Group AStreptococcalVaccines in Mice”,J. Immunol., 141(8), (1988),2767-2770.
Brummer, E. , et al., “Immunological Activation of Polymorphonuclear Neutrophilis for Fungal Killing: Studies with Murine Cells and Blastomyces Dermatitidis In Vitro”,Journal of Leukocyte Biology, 36, (1984),505-520.
Carter, Paul , et al., “Dissecting the catalytic triad of a serine protease”,Nature, vol. 332, XP002135964, (Apr. 7, 1988),564-568.
Chen, Cecil C., et al., “Complete Nucleotide Sequence of theStreptococcalC5A Peptidase Gene ofStreptococcus pyogenes”, The Journal of Bilogical Chemistry, 265(6), (1990),3161-3167.
Clark, J. , et al., “A New Method for Quantitation of Cell-Mediated Immunity in the Mouse”,Journal of the Reticuloendothelial Society, 25(3), (1979),255-267.
Cleary , P. , et al., “AStreptococcalInactivator of Chemotaxis: A new Virulence Factor Specific to Group A Specific to Group AStreptococci”, Recent Advances in Streptococci and Streptococcal Diseases(Y. Kimura, S. Kotami and Y. Shiokawa (ed). Reedbooks Itd; Berkshire, England, (1984),179-180.
Cleary , P. , et al., “Similarity Between the Group B and AStreptococcalC5a Peptidase Genes”,Infection and Immunity, 60(10), (1992),4239-4244.
Cleary , P , et al., “StreptococcalC5a Peptidase is a Highly Specific Endopeptidase”,Infection and Immunity, 60(12), (1992),5219-5223.
Cleary , P. , et al., “Virulent Human Strains of Group GStreptococciExpress a C5a Peptidase Enzyme Similar to that Produced by Group AStreptococci”, Infection and Immunity, 59(7), (Jul. 1991),2305-2310.
Courtney, H. S., et al., “Analysis of the role of M24 Protein in group AStreptococcaladhesion and colonization by use of ‘omega’-interposon mutagenesis”,Infect. Immun., 62(11), (1994),4868-4873.
Fenderson, P. , et al., “Tropomyosin Shares immunology Epitopes with Group AStreptococcalM Proteins”,The Journal of Immunology, 142(7), (Apr. 1989),2475-2481.
Fischetti, V. A., et al., “Protection against streptoccal pharyngeal colonization with vaccines composed of M protein conserved regions”,Adv. Exp. Med. Bio., 303, (1991),159-167.
Fischetti, V.A., et al., “Protection against streptococcal pharyngeal colinization with a vacine: M protein recombinant”,Science, 244, (1989),1487-1490.
Fischetti, V. , “StreptococcalM Protein: Molecular Designn and Biological Behavior”,Clinical Microbiology Reviews, 2(3), (Jul. 1989),285-314.
Hill, H. , et al., “Group BStreptococciInhibit the Chemotactic Activity of the Fifth Component of Complement”,The Journal of Immunology, 141(10), (1988),3551-3556.
Hope-Simpson, R. , “Streptococcus pyogenesin the Throat: A study in a small population, 1962-1975”,J. Hyg. Camb., 87, (1981), 109-129.
Ji, Y., et al., “C5a peptidase alters clearance and trafficking of group Astreptococciby infected mice”,Infection and Immunity, 64(2), (1996),503-510.
Ji, Y , et al., “Intranasal immunization with C5a peptidase prevents nasopharyngeal colonization of mice by the group Astreptococcus”, Infect, Immun., 65(6), (1997),2080-2087.
Kapur, V. et al., “Vaccination withstreptococcalextracellular crysteine protease (interleukin-1B convertase) protects mice against challenge with heterologous group Astreptococci”, Microbial. Path., 16(6), (1994),443-450.
Laemmli, U. K., “Cleavage of Structural Proteins during the Assembly of the Head . . . ”,Nature: International Journal of Science, vol. 227,(1970),680-685.
Lee, P. , et al., “Quantification and Toxicity of Group AStreptococcalPyrogenic Exotoxins in an Animal Model of Toxic Shock Syndrome-Like Illness”,Journal of Clinical Microbiology, 27(8), (1989), 1890-1892.
Martin, T. , et al., “The Effect of Type-Specific Polysaccharide Capsule on the Clearance of Group BStreptococcifrom the Lungs of Infant and Adult Rats”,The Journal of Infectious Diseases, 1685, (1992),306-314.
Massell, B., et al., “Rheumatic Fever FollowingStreptococcalVaccination”,JAMA, 207(6), (1969),1115-1119.
McGhee, J. , et al., “New Persp
Cleary Paul Patrick
Stafslien Deborah K.
Devi S.
Regents of the University of Minnesota
Viksnins Harris & Padys PLLP
LandOfFree
Streptococcal C5a peptidase vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Streptococcal C5a peptidase vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Streptococcal C5a peptidase vaccine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3891657